



Future Formulary Changes

CMS Formulary ID: 21043

Changes effective: 03/01/2021

Drug Name	Reason	Alternate Drugs	Tier
BANZEL 40 MG/ML ORAL ORAL SUSP	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	RUFINAMIDE 40 MG/ML ORAL ORAL SUSP-5	5
RANITIDINE HCL 150 MG ORAL TABLET	REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL	N/A	N/A
RANITIDINE HCL 25 MG/ML INJECTION VIAL	REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL	N/A	N/A
RANITIDINE HCL 300 MG ORAL TABLET	REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL	N/A	N/A
RANITIDINE HCL 15 MG/ML ORAL SYRUP	REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL	N/A	N/A
RANITIDINE HCL 50 MG/2 ML INJECTION VIAL	REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL	N/A	N/A
RANITIDINE HCL 15 MG/ML ORAL SYRUP	REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL	N/A	N/A
SAPHRIS 10 MG SUBLINGUAL TAB SUBL	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ASENAPINE MALEATE 10 MG SUBLINGUAL TAB SUBL-2	2
SAPHRIS 2.5 MG SUBLINGUAL TAB SUBL	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ASENAPINE MALEATE 2.5 MG SUBLINGUAL TAB SUBL-2	2

SAPHRIS 5 MG SUBLINGUAL TAB SUBL	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	ASENAPINE MALEATE 5 MG SUBLINGUAL TAB SUBL-2	2
TECFIDERA 120-240 MG ORAL CAPSULE DR	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	DIMETHYL FUMARATE 120-240 MG ORAL CAPSULE DR-5	5